<?xml version="1.0" encoding="UTF-8"?>
<p id="p0295">It has been posited that the antimalaric drugs chloroquine and hydroxychloroquine reduce glycosylation of ACE2, thus preventing SARS-CoV-2 from binding to host cells (
 <xref rid="bib34" ref-type="bibr">Devaux et al., 2020</xref>). Chloroquine has also been shown to inhibit quinone reductase 2, an enzyme that functions prominently in sialic acids biosynthesis (
 <xref rid="bib122" ref-type="bibr">Olofsson et al., 2005</xref>) and critical components of ligand recognition (
 <xref rid="bib92" ref-type="bibr">Kwiek et al., 2004</xref>). Many trials have recently been initiated on the real clinical usefulness of these drugs, which have been suggested to be useful in early therapy and even in the prevention of Covid-19. However, based on their established and potentially very serious side effects, these drugs should not be initiated until there is clear evidence of their efficacy for the treatment of Covid-19.
</p>
